Number of the records: 1  

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)

  1. TitleESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
    Author infoDrgoňa L. ... [et al.]
    Co-authors Drgoňa Ľuboš
    Corporation Redakcia Onkológia
    NoteClinical microbiology and infections, Jun 24, Suppl.2 (2018), S83-S94
    Sign.C 3069
    Source Onkológia. - ISSN 1336-8176. - Bratislava : SOLEN , 2018 . - Roč. 13, č. 3 (2018), s. 221
    MeSH Subject infekcie oportúnne : etiológia : prevencia a kontrola
    terapia molekulárne cielená : účinky nežiaduce
    terapia biologická : účinky nežiaduce
    bezpečnosť
    lektín 2 viažuci kyselinu sialovú, podobný imunoglobulínu : antagonisty a inhibítory
    Ki-1 antigén : antagonisty a inhibítory
    ADP-ribozyl cykláza 1 : antagonisty a inhibítory
    antigény CD40 : antagonisty a inhibítory
    rodina signálnych molekúl aktivácie lymfocytov : antagonisty a inhibítory
    receptory CCR4 : antagonisty a inhibítory
    Subj. Headings inotuzumab ozogamicin * brentuximab vedotín * daratumumab * lucatumumab * anti-SLAMF7/CD319 * elotuzumab * mogamulizumab
    LanguageEnglish
    CountrySlovak Republic
    Document kindRozpis článkov z periodík
    DatabaseARTICLES
    article

    article

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.